In this paper, we deal with the effects of interfractional organ motion during radiation therapy. We consider two problems: first, treatment plan evaluation in the presence of motion, and second, the incorporation of organ motion into IMRT optimization. Concerning treatment plan evaluation, we face the problem that the delivered dose cannot be predicted with certainty at the time of treatment planning but is associated with uncertainties. We present a method to simulate stochastic properties of the dose distribution. This provides the treatment planner with information about motion-related risks of different plans and may support the decision for or against a treatment plan. This information includes the display of probabilities of individual voxels to receive doses from a therapeutical interval or above critical levels, as well as a diagram that shows the variability of the dose volume histogram. Concerning the incorporation of organ motion into IMRT planning, we further analyse the approach of inverse planning based on probability distributions of possible patient geometries. We consider three different sources of uncertainty, namely uncertainty about the amplitude of motion, a systematic error and a random error. We analyse the impact of these sources of uncertainty on the optimized treatment plans for prostate cancer.
Introduction
In fractionated radiation therapy, treatment results are affected by organ motion, which occurs during treatment. Although this is a well-known fact, treatment plans are regularly evaluated in terms of a single dose distribution, which shows the dose that would be delivered if the patient's geometry was always like in the planning CT scan. As the patient's geometry may vary between the fractions of a treatment (or during dose delivery in a single fraction), and because these variations cannot be known prior to treatment, there are usually differences between the planned and the finally realized dose distribution (Langen and Jones 2001) .
In this paper, we propose a method to overcome this simplified notion. In the presence of organ motion, the delivered dose distribution is uncertain. The dose delivered to an element of tissue must be considered as a random variable. We present tools to assess the stochastic characteristics of a dose distribution.
A mathematical model to describe organ motion induced geometric changes of the patient is the basis of an improved description of organ motion effects on the dose distribution. With modern imaging modalities inside the treatment room, it is possible to acquire several image data sets of a patient prior to or during the first fractions of a treatment, with the patient in the treatment position. We assume that we have a set of such images, which can be used to estimate the parameters of the model of interfractional organ motion. In order to characterize the potentially delivered dose distribution, we simulate a large number of treatments with random motion parameters, drawn from the motion model.
Another aspect of this paper is the inclusion of organ motion into the treatment planning process. In this context, the current paper is the fourth paper in a series of papers dealing with the inclusion of organ motion in IMRT optimization (the previous papers are Unkelbach and Oelfke (2004 , 2005a , 2005b ). The current paper is thus an extension of the previously published work. In order to minimize redundancy, this paper is not self-contained but refers to a large extent to the previously published work. In the previous papers, we considered three types of errors that occur due to interfractional organ motion: first, random errors that describe random displacements of the tumour in different fractions; second, systematic errors that describe a shift of the true mean position of the tumour from its estimated mean position; and third, uncertainties in the magnitude of interfractional organ motion. In Unkelbach and Oelfke (2005a) , we applied the concept of Bayesian inference to formulate a motion model that describes all three types of errors within a unified framework. The motion model was used to calculate the expectation value of the dose distribution and its variance as a measure of the uncertainty of the dose prediction. The incorporation of interfractional motion into IMRT optimization was demonstrated for a model of idealized geometry. In Unkelbach and Oelfke (2005b) , we considered the application of the concept to clinical data of prostate patients. However, in this first application, we discussed random errors in detail, but we neglected systematic errors and uncertainties in the magnitude of motion.
In the current paper, we deal with the inclusion of systematic errors and an uncertain magnitude of motion into treatment plan optimization and evaluation for prostate cancer. The paper contains two major result parts. In section 3.2, we focus on the incorporation of organ motion into IMRT optimization. We analyse the impact of the three types of uncertainties on the optimized treatment plan. In brief, this part represents the transfer of the concept developed in Unkelbach and Oelfke (2005a) from an idealized geometric model to clinical data of prostate patients. In section 3.1, we investigate problems in treatment plan evaluation that generally occur in the presence of interfractional motion, independent of the foregoing treatment plan optimization method. The dose distribution becomes a random variable, which represents the underlying problem in treatment plan evaluation. In a first step, the dose delivered to a voxel can be characterized by an expectation value of the dose and its variance. However, this information may not always be easy to interpret. Therefore, we provide additional surrogates to characterize the dose. For example, we display the probability that the dose delivered to a voxel is within predefined dose intervals. Such illustrations allow for an estimation of sufficient target coverage and the risk of overdosing critical structures.
Materials and methods
In this section, we describe methods to calculate stochastic properties of a dose distribution for a given treatment plan. Section 2.1 summarizes the assumptions on the treatment planning process, section 2.2 introduces the mathematical model of internal organ motion, which is described in detail in Unkelbach and Oelfke (2005a) . Sections 2.3-2.5 describe the methods used to calculate characteristics of the random variable dose distribution based on the motion model. Section 2.6 concerns the inverse IMRT planning concept in order to include the motion model in the treatment plan optimization.
Assumptions on the treatment process
Concerning the treatment process, we apply the assumptions introduced in a previous paper (Unkelbach and Oelfke 2004) dealing with IMRT optimization for prostate cancer. The most important aspects are repeated here for convenience.
• There are one or more planning CT scans at the time of treatment planning, i.e. one planning CT scan plus additional verification scans.
• For more than one CT, voxel positions in the first CT are matched with their corresponding voxels in the other images. The resulting set of vectors can be used to estimate parameters of a motion model. • A treatment plan defines a constant dose distribution in space, which we refer to as the static dose distribution, denoted by D stat . The static dose distribution is calculated on the planning CT scan and is assumed to be unaffected by changes of the patient geometry in different fractions. Tissue elements move through this 'dose cloud' and accumulate dose. For prostate patients, this approximation may be justified. For a discussion of the validity of the 'dose cloud' method, see e.g. Bortfeld et al (2004) and the notes in the previous paper (Unkelbach and Oelfke 2005b, section IIA).
• Intrafractional organ motion is neglected.
The model of organ motion
We apply the motion model introduced in Unkelbach and Oelfke (2005a) ; this section only recalls the results and the notation needed for following sections. Movement of tissue is described as a movement of individual volume elements. Each volume element can be located at different positions r and the movement is assumed to be Gaussian, i.e. there is an assumed mean position of the tissue elementr = (x,ŷ,ẑ) plus a random displacement r −r, which is normally distributed around zero.
In this paper, we consider the simplified case that random displacements are uncorrelated in the three spatial dimensions, so that the probability distribution for a three-dimensional displacement factorizes. Therefore, we provide the formulae for a single coordinate x only. For a generalization to correlated movements in three dimensions, see Lam et al (2005) . The probability of finding a certain tissue element at a position x can be described as
The parameters of this model (x and σ x ) have to be estimated from the patient images that are obtained prior to the simulation of a plan's uncertainties. After registration of the patient images, there should be a set of M measured positions {p xµ } M µ=1 for the tissue element. For the practical estimation ofx and σ x , we use the technique of Bayesian inference, which takes into account the inevitable estimation errors. The method yields not single estimated values, but probability distributions P (x|σ x , {p xµ }) and P (σ x |{p xµ }), describing how probable each pair of parameters is-given the data measured from the patient images and (optionally) data about organ motion in previous patients. The probability thatx is the 'true' mean position of the tissue element is given by We consider two situations for the calculation of the probability distribution P (σ x |{p xµ }) for the amplitude of motion: estimation based on the patient images alone and estimation based on patient images plus motion data from previous patients.
When we base the estimation on the measured positions p xµ alone, we get
where σ
2 is the magnitude of motion estimated from the patient images.
However, there are many motion studies, performed for a variety of organs (Tinger et al 1998 , Roeske et al 1995 . Thus, it is sensible to incorporate prior knowledge about σ (which is often reported in studies) into the model. This means considering some a priori distribution P (σ x ), which describes the probabilities of different values of σ x independent of the individual patient. Using a gamma prior, the estimation for σ x is
Both parameters α and λ of the gamma prior can be expressed in terms of the expectation value σ 
For uncorrelated movement in the three spatial directions, the probability to find a tissue element at the three-dimensional position r = (x, y, z) given a mean positionr = (x,ŷ,ẑ) is given by
Also, the probability distributions P (r|σ,r) and P (σ|σ data ) factorize:
For the general case, P (r|r, σ) and P (r|σ,r) are given by three-dimensional multivariate normal distributions and P (σ|σ data ) is given by a Wishard distribution. In the case that a structure can only move as a rigid body, all tissue elements in this structure are characterized by the same parameter value for σ data . Tissue deformations can be described by allowing for different motion amplitudes σ data for different elements of a structure.
The expectation value and the variance of the dose
Based on the motion model and a given static dose distribution, we can formally define the expectation value of the cumulative dose after N fractions in a certain tissue element:
dr µ dr dσ.
(9) The dose D stat (r) refers to the dose value of the static dose field at position r. The variance of the cumulative dose is given by
where
(11) The standard deviation of the dose is the square root of the variance (SD = √ V ).
Simulation of stochastic properties
Due to the stochastic nature of interfractional organ motion, the dose applied to a tissue element is a random variable. We have to find appropriate surrogates to characterize the random variable 'dose to a tissue element'. Here, we want to calculate three types of characteristics.
(i) The expected value of the dose received by individual tissue elements.
(ii) The corresponding standard deviation of the dose received by individual tissue elements.
(iii) The probability for individual tissue elements of receiving doses within defined dose intervals. In order to calculate these quantities based on the motion model and a given static dose distribution, we implemented a stand-alone program. Concerning the expectation value and the variance of the dose, the tool performs an evaluation of the integrals in equations (9) 
The static dose distribution is assumed to be constant within a static voxel, i.e. no interpolation between neighbouring voxels is implemented.
Basically, this simulation is done for every single tissue element 2 . For example, for the expectation values of the dose in different tissue elements, we have to display a 3D spatial distribution of expectation values. The result has to be interpreted within a moving, tissuefixed coordinate system. Each tissue element has its fixed position within this system, and when tissue elements move, they change positions only in the static coordinate system of the treatment room where the static dose distribution is defined. Practically, we associate each voxel in the planning CT with a tissue element and then apply the planning CT scan to visualize the spatial distribution of dose expectation values in the deforming tissue.
For the generation of random numbers, we use two different techniques. For the distributions in equations (3) and (4), we utilize the rejection method, which is a general purpose method of random number generation, described in Press et al (1994, chapter 7. 3). The numbers from a uniform distribution, which are needed for this method, are generated by an implementation of the Mersenne twister algorithm (Matsumoto and Nishimura 1998) , which was recommended in a recent review of random number generators (L'Ecuyer 2004, chapter 2). For the normal distribution, there are much faster algorithms available for random number generation. We decided to use the FastNorm algorithm (Wallace 1996) because of its speed.
Simulation output
In this section, we describe the output of our simulations. Examples for these results will be presented in section 3.1.
Expected value and standard deviation.
The easiest way to characterize a stochastic quantity or a random variable is the expected value of that quantity, in our case the dose to a voxel. When predicting the outcome of a probability experiment, the expected value represents the best possible guess, and this is the reason why we estimate it with our simulations.
Inherently connected with the expected value is the standard deviation, which describes how far from the expected value actual realizations typically are. We estimate this measure together with the expected value, because it provides us a hint about the quality of the prediction by the expected value. If the standard deviation is small, the realizations of our random variable will most probably be found in a small region around the expected value. An increased standard deviation indicates the spreading of the observed realizations around the expected value.
According to the simulation procedure described in section 2.4, we estimate the expected value of dose D and the standard deviation SD of a tissue element with
and
with Figure 1 . A prototypic GUI for exploring dose probabilities. The user can select a dose range (listbox to the left) and can then examine the probabilities for doses below, inside and above the selected interval. VOI contours are shown for orientation. Interesting dose ranges can be exported to our treatment planning system for overlay with CT images. In the screenshot above, probabilities for doses above 75% of the prescribed dose are displayed in the rightmost window.
Probabilities of dose intervals.
A major problem with the display of an expected value of dose and its standard deviation is that it requires the observer to integrate both values into one information about the possible ranges of dose values which are possibly realized during treatment. This integration has to happen inside the observer's mind and is difficult if not impossible, because of the deficiencies of the expected value in connection with skewed or bimodal distributions. This is usually the case when systematic errors are taken into account.
Because of this problem, we propose an alternative possibility of displaying the uncertainty of the dose to a voxel. The idea we present here is that we can estimate the probability of given dose intervals. If a physician determines the relevant dose intervals for a treatment plan, one can estimate each voxel's probability of receiving doses from these intervals. This is done by counting how many of our simulated cases yield a dose inside the specified interval. Open intervals (like 'doses greater 30 Gy') can be achieved by setting one interval limit to an unreasonable high value. For example, the probability that a tissue element receives a dose within a 5% tolerance interval around a prescribed dose D CTV is approximately given by
where is the Heavyside step function, i.e.
. In practice, we do not define a single interval, but a continuous series of intervals. We calculate the probabilities of each interval and allow the user to combine several intervals he might find interesting. A graphical user interface was implemented to display and explore the variety of probability maps that are generated. In the user interface (figure 1) we do not simply display one selected interval (or set of intervals), but we show three images at once. The user has to select a continuous series of intervals to determine the interval of interest. The voxels' probabilities of receiving doses from this interval of interest are then displayed in the central window-colour coded with a look-up table. In the windows to the left and to the right, we display the probabilities for dose values below (left) and above (right) the interval of interest. These additional windows give the answer to an obvious question, which arises when the probability of the interval of interest is very low. In these cases, a user would probably want to know whether the dose will be higher or lower than the specified interval.
The advantage of these probability maps is that they can be displayed as a simple, intuitive information. The user has not to integrate several pictures into one piece of information as with the expected value and the standard deviations. Although we show three separate windows, each of them could be considered isolated, and each answers a single question, namely what is the probability of receiving a dose within a given range.
Inclusion of organ motion into the optimization
In order to integrate organ motion into IMRT optimization, we further investigate the approach of inverse planning based on probability distributions of patient geometries which has been subject to detailed investigation in the previous papers (Unkelbach and Oelfke 2004 , 2005a , 2005b . In comparison to Unkelbach and Oelfke (2005b) , which deals with random errors alone, we generalized the implementation in the inverse planning tool KonRad in order to deal with systematic errors and uncertainties in the magnitude of motion.
For the optimization of the fluence maps, we adopt the quadratic objective function that was introduced in Unkelbach and Oelfke (2005b) :
n . D CTV is the dose prescribed to the tumour, D max n is a maximum dose for the organ at risk (OAR) with index n, and α CTV and α n are penalty factors for the CTV and organs at risk, respectively. Contoured organs at risk are rectum, bladder and the pelvic bones. The unclassified tissue that surrounds the CTV and the contoured organs at risk is also treated as an organ at risk.
The index i refers to a tissue element, i.e. a voxel in the planning CT scan. The expectation value of the dose D i in voxel i is given by equation (9) and the variance V i is given by equations (10) and (11). The objective function can be minimized by means of standard gradient methods. The expectation value D i can be expressed as a linear function of the beamlet weights by defining an effective dose contribution matrix that stores the expectation value of the dose contribution of a beamlet to the voxel for unit fluence. The variance V i is evaluated by defining a variance contribution tensor that stores the variance contribution of a pair of beamlets to the voxel for unit fluence. The concept was described in Unkelbach and Oelfke (2005b) and the generalization to the extended motion model considered now is straightforward. Exemplarily, the calculation of the variance contribution tensor is described in the appendix.
Results

Tools for treatment plan evaluation
In this section, we demonstrate the application of the treatment plan evaluation tools described in section 2. We consider a treatment plan that is optimized by minimizing the objective function in equation (17). It is assumed that M = 5 CT scans are performed prior to treatment and that the following set of motion model parameters was estimated from these images for all voxels:
(3 mm, 4 mm, 3 mm), where the x-coordinate corresponds to the LR direction, the y-coordinate to the AP direction and the z-coordinate to the CC direction 3 . No prior knowledge about the amplitude of motion is incorporated. The estimated mean positions r for the tissue elements are assumed to be identical to their respective positions in the planning CT. The treatment plan is optimized for N = 30 fractions. For a clinical application, the 3D distribution for σ data and mean positions of the tissue elements had to be estimated from the images of the individual patient as described in section 2.2. Due to ongoing work on elastic image registration in our department, we have not yet realized this approach and demonstrate the treatment plan evaluation tools for this idealized movement.
Figure 2(a) shows the static dose distribution of the optimized treatment plan for a prostate patient. As expected, the static dose distribution shows some moderate dose peaks at the edge of the tumour. The highest dose peaks are approximately 110% of the prescribed dose. In figure 2(b) , the modulation pattern of the static dose field is illustrated in more detail. It shows the difference of the static dose and the prescribed dose in each voxel. The static dose distribution is important to understand the generic features of the probabilistic treatment planning approach. However, it is per definition not the dose distribution we expect to be realized in the patient. In the context of treatment plan evaluation we are primarily interested in assessing the dose that is finally delivered to the patient. We can look at the expectation value of the dose (figure 2(c)) which provides the best estimate of the delivered dose for each voxel. The overall expectation value of the dose is relatively difficult to interpret because the expected dose can never be realized in all voxels simultaneously. The expectation value involves averaging over the systematic error and different magnitudes of motion. This averaging process occurs only for a population of patients but not for the individual patient. The spatial 3D distribution of dose expectation values is therefore not a good surrogate for the delivered dose distribution as a whole. It has to be interpreted for each voxel separately. Since we know that the expectation value is not realized, we can in addition look at the overall uncertainty of this dose prediction, too, i.e. the standard deviation in figure 2(d) . The dose uncertainty is relatively small in the inner region of the CTV (in the order of 1-2% of the prescribed dose). At the edge of the CTV, the standard deviation is approximately 5% of the prescribed dose. The largest values occur in the adjacent healthy tissue above and below the CTV, with peaks of 10-15% of the prescribed dose.
One aspect of treatment plan evaluation is to ensure a sufficient target coverage. To assess the target coverage, the treatment planner has to combine the information of the expectation value and the standard deviation. When the expected dose in a voxel is close to the prescribed dose and the standard deviation of the dose is small, this voxel will very likely receive a sufficient dose. Figure 2(e) shows the probability that a voxel receives a dose within a 5% tolerance interval around the prescribed dose. Such an illustration allows for directly assessing the probability of sufficient target coverage. It may be a valuable tool for treatment plan evaluation. Similar pictures can be used to estimate the risk for overdosing an organ at risk. Figure 2(f) shows the probability that a voxel receives a dose above 75% of the prescribed dose.
Figure 2(g) shows the expectation value of the dose for a certain realization of the motion model parametersr and σ. We chooser −r = 0 and σ = M M−1 σ data . Thus, the blurring of the static dose distribution is due to the random error only. Figure 2 (g) is therefore a better surrogate for the 3D dose distribution which may approximately be realized (in contrast to the overall expectation value in figure 2(c) ). However, it does not contain the information about the systematic error. Figure 2(h) shows the probability that a voxel receives a dose 3 The factor M−1 M is introduced in order to make 3 mm and 4 mm the unbiased estimates of the standard deviation of voxel displacements whereas σ data refers to the maximum likelihood estimate (Unkelbach and Oelfke 2005a). 
Dose/Prob SD Difference Figure 2 . 3D distributions for treatment plan evaluation in the presence of interfractional organ movement: (a) static dose distribution; (b) difference of static dose and prescribed dose; (c) overall expectation value of the dose; (d) overall standard deviation of the dose; (e) probability that a voxel receives a dose within a 5% tolerance interval around the prescribed dose; (f) probability that a voxel receives a dose above 75% of the prescribed dose; (g) expectation value of the dose for a certain realization of the motion model parameters; (h) probability that a voxel receives a dose within a 5% tolerance interval around the prescribed dose given a certain realization of the motion model parameters; (i-k) colour coding for dose/probability, standard deviation and dose difference, respectively (in per cent of the prescribed dose).
within a 5% tolerance interval around the prescribed dose given the realization of the motion model parametersr −r = 0 and σ = M M−1 σ data . It can, for example, be observed that voxels in the most caudal part of the prostate will probably be overdosed. Figure 2(h) shows that the probability for delivering a dose within the 5% tolerance interval is quite low and in combination with figure 2(b) one can conclude that these voxels will mostly be overdosed. This information is not that obvious in figure 2(e) which involves the averaging over the systematic error and different magnitudes of motion. Figure 2 indicates that a large variety of pictures can be used to assess the dose distribution delivered to the patient. None of them seems to be perfect or even sufficient all alone. At the current stage, it is not clear which type of illustration will turn out most useful in a clinical environment. The suggested method of displaying the probability that a certain dose is absorbed in a tissue element may be helpful. We would like to emphasize that the treatment evaluation tools are independent of the foregoing optimization method to generate the treatment plan. They can also be applied to treatment plans that were produced by the standard safety margin approach. However, in the context of probabilistic treatment planning, these tools are of particular importance due to the modulation of the static dose distribution.
Analysing the impact of different uncertainties on the optimized treatment plan
In this section, we analyse the impact of the three sources of uncertainty on the optimized treatment plan, i.e. uncertainties in the magnitude of motion (P (σ|σ data )), systematic errors (P (r|r, σ)), and random errors (P (r|r, σ) ). In analogy to the previous paper (Unkelbach and Oelfke 2005a), we compare three different cases. In other words, we compare inverse planning based on the general motion model described in section 2.2 to simplified approaches where uncertainties in σ or both σ andr are neglected. We consider the same parameter set as in section 3.1, i.e. N = 30 fractions, M = 5 CT scans, estimated amplitudes
data of motion of 4 mm in AP and 3 mm in the LR/CC direction. No prior knowledge about the amplitude of motion is incorporated. All treatment plans are optimized using the same set of penalty factors and maximum dose values in the objective function. Figure 3 shows the modulation of the static dose distribution for the three treatment plans. It is observed that the modulation patterns of the static dose distributions are similar for all three treatment plans 4 . The major difference between the three treatment plans is that the high dose region is more expanded into the healthy tissue when more uncertainties are taken all uncertainties systematic and random only random tumour (b) (a) Figure 4 . Analysis of the impact of different uncertainties for treatment plan 1 (optimized by incorporating random errors only). For this treatment plan, we retrospectively calculate the probability P 95−105 three times while allowing for an increasing amount of uncertainty: (a) shows the probability that the delivered dose is within a 5% tolerance interval around the prescribed dose and (b) shows the standard deviation of the dose.
into account. It is intuitive that the inclusion of systematic errors should not change the modulation pattern too much. For the individual patient, the averaging process that levels out the static dose inhomogeneities is only due to the random error which remains the same. The expansion of the volume irradiated with a high dose can be observed by a careful comparison of figures 3(a)-(c).
If systematic errors and uncertainties in the magnitude of motion are neglected during optimization and evaluation of the treatment plan, this may lead to an insufficient CTV coverage. Figure 4(a) shows profiles of the probabilities P 95−105 that the dose delivered to a voxel is within a 5% tolerance interval around the prescribed dose. For treatment plan 1, the probabilities P 95−105 are retrospectively calculated three times by allowing for an increasing amount of uncertainty. The dotted line shows P 95−105 calculated by allowing for random errors only (like during the optimization). The curve suggests a sufficient target coverage. When, in addition, systematic errors (dashed line) and uncertainties in the magnitude of motion (solid line) are incorporated in the calculation of P 95−105 , the probability for sufficient target coverage at the edge of the CTV decreases. This is closely related to an increase of the dose uncertainty as depicted in figure 4(b) . Random errors alone result in relatively small dose uncertainties (dotted line). In this profile, the standard deviation of the dose is approximately 2% of the prescribed dose at the edge of the tumour. When systematic errors (dashed line) and uncertainties in the magnitude of motion (solid line) are additionally incorporated into the calculation of the standard deviation, the uncertainty at the edge of the tumour increases up to approximately 6% of the prescribed dose. Figure 5 compares the three treatment plans shown in figure 3. For the three different static dose distributions, we retrospectively calculate the standard deviation of the dose and the probabilities P 95−105 by incorporating all three types of uncertainties. The standard deviation in figure 5(b) illustrates that the magnitude of the dose uncertainty in the transition region between tumour and healthy tissue cannot be reduced significantly by incorporating all uncertainties into the optimization. However, for treatment plan 3 which incorporates all three types of uncertainties during the optimization, the region of large dose uncertainty is shifted towards the healthy tissue (solid line). This results in a higher probability for sufficient target coverage ( figure 5(a) ). The effect is essentially achieved by an expansion of the high dose region which can be observed by carefully comparing figures 3(a)-(c). In the previous paper (Unkelbach and Oelfke 2005a), we analysed inverse planning based on probability distributions of patient geometries for an idealized model. In this work, we find that the generic features of the approach observed for the idealized model are widely reproduced in the application to clinical data.
Adaptive treatment planning
In sections 3.1 and 3.2, we assumed that M = 5 CT scans are available for treatment planning before the first fraction. In a clinical environment, this may not apply. The number of CT scans may increase during the course of treatment. A realistic scenario may be that a CT scan is acquired in each fraction during the first week of treatment. In the framework of a single adaptation strategy, this information could be used for a single replanning to obtain a modified treatment plan that is applied in the remaining fractions. It was suggested (Birkner et al 2003) that the treatment plan for the first part of treatment could be optimized by using the standard safety margin approach, whereas the second treatment plan is optimized based on the acquired images during the first fractions. Following this approach, the inverse planning concept discussed in this paper provides an improved method for optimizing the second treatment plan for the remaining fractions.
Potential variation in dose volume histograms
Besides the voxel based information of the previous sections, we wanted to have some global plan evaluation means with added information about uncertainty. We propose to display the possible volume variations of a dose volume histogram (DVH). A DVH shows for certain dose intervals the amount of volume which will receive a dose from that interval. The most common form of the DVH is the cumulative DVH, where for each dose the volume which receives a certain dose or a higher dose is shown.
One difference to the methods of section 2.4 is important. When calculating a DVH, one cannot treat each voxel independently. The entirety of all voxel positions in each treatment fraction has to represent a valid patient geometry. This must at least be true for each organ or volume of interest (VOI), otherwise the recorded DVHs would be unrealistic. A general method to parameterize geometric changes of the patient's geometry as a whole is provided by a principal component analysis which has been presented for internal prostate movements (Söhn et al 2005) . Here, we consider the idealized case of rigid movements of the prostate, i.e. all tissue elements of the prostate are characterized by the same parameter σ data . A model to describe the geometric changes of the rectum has to be more complex than a rigid translation. In order to simulate variations of the DVH, we perform a similar procedure as described in section 2.4, except that for all voxels of the prostate the same displacements are used. For the centre of the prostate we (i) generate a magnitude of motion using equation (3), (ii) calculate a systematic displacement of the mean position from the estimated mean position based on the multiple CT images (equation (2)) and (iii) find N random displacements for the daily deviation of the prostate's position from its mean position (equation (1)).
The same total displacements are then applied to all voxels of the prostate in order to accumulate dose. We calculate the cumulative 3D dose distribution and the DVH for this treatment sample. Performing Q treatment simulations, we obtain Q samples of a possible DVH. For each dose value D on the abscissa, we can then display a box plot that displays the distribution of the simulated volumes. A very space saving version (from (Tufte 1983) [p 125]) of the box plot is used to fit a whole series of box plots in one diagram. From these box plots an observer obtains various data, e.g. whether the volume receiving doses above some critical value is considerably large in most cases, or whether it is acceptable in 95% of all treatments. The median DVH tells the volume which receives a dose higher than D in 50% of the simulations. Figure 6 shows the uncertain DVH for the treatment plan discussed in section 3.1. The crosses show the median DVH. For example, in 50% of all simulations, a volume larger than approximately 92% of the prostate receives a dose higher than 95% of the prescribed dose. The upper and lower end points of the bars below the median DVH show the 25% quantile and the 2.5% quantile, respectively. For example, in 2.5% of the simulations, a volume lower than 68% of the prostate received a dose higher than 95% of the prescribed dose. The bars above the median DVH, in analogy, show the 75% quantile and 97.5% quantile. For example, in 50% of the simulations, a volume between 86% and 96% of the prostate received a dose higher than 95% of the prescribed dose. From the uncertainty added DVH, an observer can e.g. see whether a significant fraction of the CTV receives a dose below some critical value in many cases, or whether the target coverage is acceptable in almost all the treatments.
Discussion
In this paper, we deal with uncertainties of the dose distribution which occur as a result of interfractional organ motion. Organ motion was simulated based on a Gaussian distribution to describe the interfractional displacements of the prostate. We considered three sources of uncertainty: random errors, systematic errors and uncertainties in the magnitude of motion. The motion model was introduced in a previous paper (Unkelbach and Oelfke 2005a) and demonstrated in the context of a very idealized geometry. In this paper, an application to clinical data of prostate cancer patients is provided.
We addressed two problems: first, the problem of treatment plan evaluation in the presence of interfractional motion, and second, the inclusion of organ motion in IMRT optimization by means of inverse planning based on probability distributions, also referred to as probabilistic treatment planning.
In the context of interfractional organ motion, the dose cannot be predicted with certainty but becomes a random variable. With regards to treatment plan evaluation, different surrogates can be used to assess the potentially delivered dose. One method is to display two colourcoded maps of the expected values of dose and the associated standard deviations overlaid on the planning CT. A major drawback of this method is that information from both maps has to be combined inside the observer's mind in order to estimate the risk of overdosing or underdosing a structure. We try to solve this problem by calculating the probability that the delivered dose to a voxel is within a predefined dose interval. The resulting probability maps are intuitive and relatively easy to interpret. They may prove helpful for assessing the probability for sufficient target coverage or the risk of overdosing a critical structure. The developed tools are independent of the treatment plan optimization method. However, they are of particular interest in the context of probabilistic treatment planning.
Regarding the inclusion of organ motion in IMRT optimization, we further investigated the approach of inverse planning based on probability distributions. This method was introduced in previous papers and the current one is an extension of the previous work. We investigated the impact of the three sources of uncertainty (random errors, systematic errors and uncertainties in the magnitude of motion) on the optimized treatment plan for a prostate case. It was observed that the inclusion of systematic errors and uncertainties in the magnitude of motion into the optimization leads to qualitatively similar treatment plans compared to the simplified case where only random errors are incorporated (this simplified case was extensively discussed in Unkelbach and Oelfke (2005b) ). The inclusion of additional uncertainties primarily leads to an increase of the integral dose, i.e. an extension of the region around the target which is irradiated with a high dose. We demonstrated the feasibility of including multiple uncertainties including systematic errors into the probabilistic optimization of a treatment plan in order to make this a more general and robust approach.
Appendix. Evaluation of the variance during the optimization
The variance V i in voxel i is is the dose contribution of beamlet α to the point r µ in the static coordinate system. The integrals in (A.2) are evaluated by Monte Carlo calculation for the dose distributions of all pairs of beamlets α and β using the procedure described in section 2.4.
